GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Valuation Rank

argenx SE (XBRU:ARGX) Valuation Rank


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

argenx SE Valuation Rank Related Terms

Thank you for viewing the detailed overview of argenx SE's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Valuation Rank
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:ONWD XBRU:HYL XBRU:ALEMS XBRU:BIOS XBRU:OXUR VRTX ASX:CSL REGN XKRX:207940 ALNY ONC XKRX:068270 BNTX SMMT INSM HKSE:02269 BMRN RPRX
Traded in Other Exchanges
ARGX:USA ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany A1RG34:Brazil ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.